Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histology and immunohistochemistry (CD20+) confirmed Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), or histology confirmed KSHV-associated multicentric Castleman disease with elevated blood KSHV viral load~* Cohort 1: Age should be equal to or greater than 15~* Cohort 2: Age: 2-15~* Measurable disease~* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2~* Able to provide informed consent (adults) or assent (children \< 18 years) in English or Luganda~* Human immunodeficiency virus (HIV)-infected patients eligible if meet the following criteria:~  * CD4+ T-cell count \> 200 cells/uL~ * HIV treatable with effective antiretroviral therapy that does not include agents with known significant drug-drug interactions with accompanying chemotherapy (ritonavir and cobicistat contraindicated)~Exclusion Criteria:~* Previous therapy for lymphoma or KSHV-multicentric Castleman disease (MCD)~* History of hypersensitivity to rituximab~* Pregnant or nursing women. Men or women may not participate unless they have agreed to use effective contraception during treatment and for 12 months following completion of therapy~* Inadequate organ function, unless attributed to lymphoma or KSHV-MCD~* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2.5 times upper limit of normal~* Creatinine \> 2 times upper limit than normal or calculated creatinine clearance \< 60 mL/min~* New York Heart Association (NYHA) cardiac failure class III or IV~* Patients with clinically significant anemia-hemoglobin less than 10 g/dL~* Central nervous system (CNS) masses consistent with lymphoma or untreated infection; leptomeningeal disease will not be excluded~* Patients with malignancy within 5 years, other than resected local skin cancer or limited Kaposi sarcoma (KS) (no known pulmonary KS)~* Patients with evidence of active infections including malaria and hepatitis B (participants with hepatitis B virus \[HBV\] controlled on antivirals will not be excluded)

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort I (pediatric BL) (Type: EXPERIMENTAL): Patients receive cyclophosphamide IV and vincristine IV on day 1, and prednisone IV or PO on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients then receive rituximab IV or rituximab hyaluronidase SC, cyclophosphamide IV, vincristine IV, and methotrexate IV on day 1. Cycles repeat every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
- Cohort II (DLBCL) (Type: EXPERIMENTAL): Patients receive rituximab IV or rituximab and hyaluronidase human SC, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1, and prednisone PO on days 1-5 of cycle 1. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
- Cohort III (Adult BL) (Type: EXPERIMENTAL): Patients receive rituximab IV or rituximab and hyaluronidase human SC in day 1, etoposide IV, doxorubicin IV, and vincristine IV on days 1-4. Patients also receive cyclophosphamide IV on day 5 and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
- Cohort IV (MCD) (Type: EXPERIMENTAL): Patients receive rituximab IV or rituximab and hyaluronidase human SC on days 1, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).